| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥204.02B | ¥209.16B | -2.5% |
| Cost of Sales | ¥153.32B | ¥161.89B | -5.3% |
| Gross Profit | ¥50.70B | ¥47.27B | +7.2% |
| SG&A Expenses | ¥38.91B | ¥40.34B | -3.6% |
| Operating Income | ¥11.79B | ¥6.93B | +70.1% |
| Non-operating Income | ¥1.46B | ¥1.69B | -13.6% |
| Non-operating Expenses | ¥3.19B | ¥5.44B | -41.3% |
| Ordinary Income | ¥10.06B | ¥3.18B | +216.3% |
| Profit Before Tax | ¥7.03B | ¥2.31B | +204.0% |
| Income Tax Expense | ¥436M | ¥165M | +164.2% |
| Net Income | ¥6.60B | ¥2.15B | +207.0% |
| Net Income Attributable to Owners | ¥5.73B | ¥114M | +4928.1% |
| Total Comprehensive Income | ¥8.04B | ¥2.02B | +298.5% |
| Depreciation & Amortization | ¥11.84B | ¥11.18B | +5.9% |
| Interest Expense | ¥1.39B | ¥917M | +51.7% |
| Earnings per Unit (EPU) | ¥64.98 | ¥1.29 | +4937.2% |
| Distribution per Unit (DPU) | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥255.66B | ¥267.50B | ¥-11.84B |
| Cash and Deposits | ¥26.04B | ¥28.58B | ¥-2.54B |
| Accounts Receivable | ¥79.34B | ¥92.55B | ¥-13.20B |
| Inventories | ¥66.81B | ¥65.06B | +¥1.76B |
| Non-current Assets | ¥353.91B | ¥350.30B | +¥3.61B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥27.53B | ¥17.10B | +¥10.43B |
| Investing Cash Flow | ¥-17.08B | ¥-24.34B | +¥7.26B |
| Financing Cash Flow | ¥-12.98B | ¥1.28B | ¥-14.26B |
| Free Cash Flow | ¥10.45B | - | - |
| Item | Value |
|---|---|
| Book Value Per Share | ¥2,253.10 |
| Net Profit Margin | 2.8% |
| Gross Profit Margin | 24.8% |
| Current Ratio | 181.4% |
| Quick Ratio | 134.0% |
| Debt-to-Equity Ratio | 1.60x |
| Interest Coverage Ratio | 8.48x |
| EBITDA Margin | 11.6% |
| Effective Tax Rate | 6.2% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -2.5% |
| Operating Income YoY Change | +70.1% |
| Ordinary Income YoY Change | +216.3% |
| Net Income Attributable to Owners YoY Change | -94.3% |
| Total Comprehensive Income YoY Change | +298.4% |
| Item | Value |
|---|---|
| Units Outstanding (incl. Treasury) | 89.05M shares |
| Treasury Units | 803K shares |
| Average Units Outstanding | 88.20M shares |
| NAV per Unit | ¥2,660.46 |
| EBITDA | ¥23.63B |
| Item | Amount |
|---|---|
| Q2 Distribution | ¥0.00 |
| Year-End Distribution | ¥40.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| LifeScience | ¥16.63B | ¥149M |
| RealEstate | ¥2.81B | ¥979M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥425.00B |
| Operating Income Forecast | ¥23.00B |
| Ordinary Income Forecast | ¥17.50B |
| Net Income Attributable to Owners Forecast | ¥6.50B |
| Earnings per Unit Forecast (EPU) | ¥73.69 |
| Distribution per Unit Forecast (DPU) | ¥40.00 |
| Property, Plant & Equipment | ¥300.35B | ¥296.52B | +¥3.83B |
| Intangible Assets | ¥4.92B | ¥5.03B | ¥-111M |
| Total Assets | ¥609.57B | ¥617.80B | ¥-8.23B |
| Current Liabilities | ¥140.95B | ¥160.32B | ¥-19.37B |
| Accounts Payable | ¥43.50B | ¥48.39B | ¥-4.89B |
| Short-term Loans | ¥50.73B | ¥53.04B | ¥-2.31B |
| Non-current Liabilities | ¥233.84B | ¥225.44B | +¥8.41B |
| Long-term Loans | ¥112.75B | ¥114.34B | ¥-1.59B |
| Total Liabilities | ¥374.80B | ¥385.75B | ¥-10.96B |
| Total Equity | ¥234.77B | ¥232.04B | +¥2.73B |
| Capital Stock | ¥51.73B | ¥51.73B | ¥0 |
| Capital Surplus | ¥32.65B | ¥32.66B | ¥-12M |
| Retained Earnings | ¥71.25B | ¥68.97B | +¥2.28B |
| Treasury Stock | ¥-844M | ¥-925M | +¥81M |
| Owners' Equity | ¥198.82B | ¥195.31B | +¥3.51B |
| Working Capital | ¥114.71B | - | - |